EA201692469A1 - Производное 2-ациламинотиазола или его соль - Google Patents
Производное 2-ациламинотиазола или его сольInfo
- Publication number
- EA201692469A1 EA201692469A1 EA201692469A EA201692469A EA201692469A1 EA 201692469 A1 EA201692469 A1 EA 201692469A1 EA 201692469 A EA201692469 A EA 201692469A EA 201692469 A EA201692469 A EA 201692469A EA 201692469 A1 EA201692469 A1 EA 201692469A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- dysfunction
- bladder
- urinary
- preventing
- muscarinic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Предоставлено соединение, которое полезно в качестве активного ингредиента в фармацевтической композиции для профилактики или лечения дисфункции накопления мочи, дисфункции мочеиспускания, дисфункции нижних мочевыводящих путей и тому подобного. Авторы настоящего изобретения обнаружили, что производное тиазола, замещенное пиразинилкарбониламино в положении 2, является превосходным аллостерическим положительным модулятором мускаринового рецептора Ми предполагается в качестве средства для профилактики или лечения заболеваний мочевого пузыря/мочевыводящих путей, связанных с сокращением мочевого пузыря через посредство мускаринового рецептора М, таким образом, осуществив настоящее изобретение. Производное 2-ациламинотиазола или его соль по настоящему изобретению предполагается в качестве средства для профилактики или лечения заболеваний мочевого пузыря/мочевыводящих путей, связанных с сокращением мочевого пузыря через посредство мускаринового рецептора М, например дисфункции мочеиспускания, такой как гипоактивность мочевого пузыря.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014118046 | 2014-06-06 | ||
PCT/JP2015/066321 WO2015186821A1 (ja) | 2014-06-06 | 2015-06-05 | 2-アシルアミノチアゾール誘導体またはその塩 |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201692469A1 true EA201692469A1 (ru) | 2017-05-31 |
EA031866B1 EA031866B1 (ru) | 2019-03-29 |
Family
ID=54766887
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201692469A EA031866B1 (ru) | 2014-06-06 | 2015-06-05 | Производное 2-ациламинотиазола или его соль |
Country Status (34)
Country | Link |
---|---|
US (2) | US9951060B2 (ru) |
EP (1) | EP3153511B1 (ru) |
JP (1) | JP6319436B2 (ru) |
KR (1) | KR102482844B1 (ru) |
CN (2) | CN106414438B (ru) |
AR (1) | AR100748A1 (ru) |
AU (1) | AU2015269449B2 (ru) |
BR (1) | BR112016028270B1 (ru) |
CA (1) | CA2950564C (ru) |
CO (1) | CO2017000044A2 (ru) |
CY (1) | CY1122290T1 (ru) |
DK (1) | DK3153511T3 (ru) |
EA (1) | EA031866B1 (ru) |
ES (1) | ES2732066T3 (ru) |
HR (1) | HRP20190943T1 (ru) |
HU (1) | HUE043496T2 (ru) |
IL (1) | IL249356B (ru) |
LT (1) | LT3153511T (ru) |
MA (1) | MA39950B1 (ru) |
ME (1) | ME03438B (ru) |
MX (1) | MX370140B (ru) |
MY (1) | MY197712A (ru) |
NZ (1) | NZ727142A (ru) |
PH (1) | PH12016502405B1 (ru) |
PL (1) | PL3153511T3 (ru) |
PT (1) | PT3153511T (ru) |
RS (1) | RS58809B1 (ru) |
SA (1) | SA516380427B1 (ru) |
SG (2) | SG10202000463YA (ru) |
SI (1) | SI3153511T1 (ru) |
TR (1) | TR201908676T4 (ru) |
TW (2) | TWI689507B (ru) |
UA (1) | UA122208C2 (ru) |
WO (1) | WO2015186821A1 (ru) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8750295B2 (en) | 2006-12-20 | 2014-06-10 | Gvbb Holdings S.A.R.L. | Embedded audio routing switcher |
EP3196200B1 (en) | 2014-08-26 | 2019-05-08 | Astellas Pharma Inc. | 2-aminothiazole derivatives or salt thereof as muscarinic m3 ligands for the treatment of bladder diseases |
RU2769693C2 (ru) | 2016-12-19 | 2022-04-05 | Новартис Аг | Новые производные пиколиновой кислоты и их применение в качестве промежуточных соединений |
WO2019189766A1 (ja) * | 2018-03-30 | 2019-10-03 | 持田製薬株式会社 | 新規ビアリールアミド誘導体 |
CN111718293A (zh) * | 2019-03-18 | 2020-09-29 | 持田制药株式会社 | 双芳基酰胺衍生物的制造方法 |
EP3967311A1 (en) | 2020-09-11 | 2022-03-16 | Astellas Pharma Inc. | Compounds for use in the treatment of dry mouth |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA73543C2 (ru) | 1999-12-07 | 2005-08-15 | Тераванс, Інк. | Производные мочевины, фармацевтическая композиция и применение производного при приготовлении лекарственного средства для лечения заболевания, которое опосредствуется мускариновым рецептором |
JP2001278872A (ja) * | 2000-03-27 | 2001-10-10 | Banyu Pharmaceut Co Ltd | 新規アミノチアゾール誘導体 |
DE60114413T2 (de) * | 2000-05-25 | 2006-07-27 | F. Hoffmann-La Roche Ag | Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten |
JPWO2003037862A1 (ja) * | 2001-10-30 | 2005-02-17 | 日本新薬株式会社 | アミド誘導体及び医薬 |
ES2610611T3 (es) | 2002-01-18 | 2017-04-28 | Astellas Pharma Inc. | Derivado de 2-acilaminotiazol o sal del mismo |
TWI242478B (en) | 2002-08-01 | 2005-11-01 | Masami Nakamoto | Metal nanoparticle and process for producing the same |
AR040779A1 (es) * | 2002-08-06 | 2005-04-20 | Glaxo Group Ltd | Compuesto de tiazol anilina su uso para preparar una formulacion farmaceutica dicha formulacion recipiente que la contiene y dispositivo adaptado para la administracion intranasal de la formulacion |
MXPA06000441A (es) | 2003-07-17 | 2006-04-05 | Astellas Pharma Inc | Derivado de 2-acilaminotiazole o sal del mismo. |
JP4665769B2 (ja) | 2005-01-12 | 2011-04-06 | アステラス製薬株式会社 | アシルアミノチアゾール誘導体の製造法 |
JP4774995B2 (ja) | 2005-01-12 | 2011-09-21 | アステラス製薬株式会社 | アシルアミノチアゾール誘導体を有効成分とする医薬組成物 |
CN101490003A (zh) * | 2006-04-24 | 2009-07-22 | 阿斯利康(瑞典)有限公司 | 具有毒蕈碱m3受体拮抗剂活性、用于治疗入慢性支气管阻塞、哮喘和膀胱过动的新型环状氨基醇的取代烷基酯类化合物 |
WO2009054468A1 (ja) | 2007-10-24 | 2009-04-30 | Astellas Pharma Inc. | アゾールカルボキサミド化合物又はその塩 |
HUE052110T2 (hu) * | 2010-07-29 | 2021-04-28 | Rigel Pharmaceuticals Inc | AMPK-t aktiváló heterociklusos vegyületek és alkalmazásuk |
TWI647227B (zh) * | 2013-02-28 | 2019-01-11 | 日商安斯泰來製藥股份有限公司 | 2-醯胺噻唑衍生物或其鹽 |
-
2015
- 2015-06-05 US US15/316,645 patent/US9951060B2/en not_active Ceased
- 2015-06-05 CN CN201580030154.8A patent/CN106414438B/zh active Active
- 2015-06-05 TW TW104118315A patent/TWI689507B/zh active
- 2015-06-05 EP EP15803484.3A patent/EP3153511B1/en active Active
- 2015-06-05 TW TW109106548A patent/TWI745877B/zh active
- 2015-06-05 UA UAA201700205A patent/UA122208C2/uk unknown
- 2015-06-05 AU AU2015269449A patent/AU2015269449B2/en active Active
- 2015-06-05 BR BR112016028270-1A patent/BR112016028270B1/pt active IP Right Grant
- 2015-06-05 US US16/856,738 patent/USRE49111E1/en active Active
- 2015-06-05 PT PT15803484T patent/PT3153511T/pt unknown
- 2015-06-05 MX MX2016016134A patent/MX370140B/es active IP Right Grant
- 2015-06-05 JP JP2016525246A patent/JP6319436B2/ja active Active
- 2015-06-05 SI SI201530787T patent/SI3153511T1/sl unknown
- 2015-06-05 DK DK15803484.3T patent/DK3153511T3/da active
- 2015-06-05 RS RS20190710A patent/RS58809B1/sr unknown
- 2015-06-05 ES ES15803484T patent/ES2732066T3/es active Active
- 2015-06-05 NZ NZ727142A patent/NZ727142A/en unknown
- 2015-06-05 PL PL15803484T patent/PL3153511T3/pl unknown
- 2015-06-05 LT LTEP15803484.3T patent/LT3153511T/lt unknown
- 2015-06-05 SG SG10202000463YA patent/SG10202000463YA/en unknown
- 2015-06-05 ME MEP-2019-163A patent/ME03438B/me unknown
- 2015-06-05 KR KR1020177000217A patent/KR102482844B1/ko active IP Right Grant
- 2015-06-05 CA CA2950564A patent/CA2950564C/en active Active
- 2015-06-05 HU HUE15803484A patent/HUE043496T2/hu unknown
- 2015-06-05 CN CN201911226515.2A patent/CN110845490B/zh active Active
- 2015-06-05 TR TR2019/08676T patent/TR201908676T4/tr unknown
- 2015-06-05 SG SG11201610201UA patent/SG11201610201UA/en unknown
- 2015-06-05 EA EA201692469A patent/EA031866B1/ru not_active IP Right Cessation
- 2015-06-05 WO PCT/JP2015/066321 patent/WO2015186821A1/ja active Application Filing
- 2015-06-05 MA MA39950A patent/MA39950B1/fr unknown
- 2015-06-05 MY MYPI2016704529A patent/MY197712A/en unknown
- 2015-06-05 AR ARP150101792A patent/AR100748A1/es active IP Right Grant
-
2016
- 2016-12-02 PH PH12016502405A patent/PH12016502405B1/en unknown
- 2016-12-04 IL IL24935616A patent/IL249356B/en active IP Right Grant
- 2016-12-05 SA SA516380427A patent/SA516380427B1/ar unknown
-
2017
- 2017-01-04 CO CONC2017/0000044A patent/CO2017000044A2/es unknown
-
2019
- 2019-05-22 HR HRP20190943TT patent/HRP20190943T1/hr unknown
- 2019-06-19 CY CY20191100631T patent/CY1122290T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201692469A1 (ru) | Производное 2-ациламинотиазола или его соль | |
EA201591391A1 (ru) | Производное 2-ациламинотиазола или его соль | |
MA44486A (fr) | Procédés d'intervention précoce pour prévenir ou atténuer la toxicité | |
MA41265A (fr) | Compositions pour administration de médicaments iléo-jéjunal. | |
CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
EA201691988A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
MA55629A (fr) | Compositions d'anticorps pour le traitement de tumeurs | |
MA46981A (fr) | Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine | |
EA201790785A1 (ru) | Производные тетрагидроизохинолина | |
MA41041A (fr) | Dérivés de benzothiazole substitués utilisés en tant qu'agonistes de gpr40 pour le traitement du diabète de type ii | |
MA51337A (fr) | Inhibiteurs spiro exo-aza de l'interaction ménine-mll | |
EA201791696A1 (ru) | Композиция для лечения веноокклюзионной болезни печени | |
FR3022462B1 (fr) | Composition orale d'anticorps anti-tnfalpha | |
BR112016026552A8 (pt) | derivados de carboxamida, seus usos, composição farmacêutica, e combinação | |
EA201692298A1 (ru) | Производные карбоксамидов | |
MA49152A (fr) | Schémas posologiques d'immunoconjugués anti-cd33 | |
EA201990095A1 (ru) | КОНДЕНСИРОВАННЫЕ ТИОФЕНОВЫЕ ПРОИЗВОДНЫЕ, ПРИЕМЛЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ NAPI-IIb | |
EA201792264A1 (ru) | Способы лечения воспалительных заболеваний | |
MA46759A (fr) | Dosage de conjugués anticorps-médicament anti-cd30 pour humain non adulte | |
BR112017018192A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica. | |
EA201790020A1 (ru) | Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний | |
BR112018002138A2 (pt) | composto 2-(5 s-metil-2-oxo-4r-fenil-pirrolidin-1-il)-acetamida, uso, composição farmacêutica e método para a profilaxia ou o tratamento de convulsões | |
CL2017000026A1 (es) | Formas de dosificación farmacéutica | |
TR201908031T4 (tr) | İdrar kesesi hastalıklarının tedavisine yönelik muskarinik m3 ligandları olarak 2-aminotiyazol türevleri veya bunların tuzu. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): TM |